Loading
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Latest quote
HK$8.77
−HK$0.09 · -1.02%
Regular session · HKT · Market data may be delayed.
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Day range
Current HK$8.77
52-week range
Current HK$8.77
Regular session · HKT · Market data may be delayed.
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Day range
Current HK$8.77
52-week range
Current HK$8.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 551.58M CNY | 640.08M CNY | 218.77M CNY | 166.85M CNY | 146.02M CNY |
| Cost of goods sold | 124.91M CNY | 60.32M CNY | 55.24M CNY | 44.21M CNY | 3.03M CNY |
| Gross profit | 426.67M CNY | 579.77M CNY | 163.54M CNY | 122.64M CNY | 142.99M CNY |
| Research and development | 494.34M CNY | 404.15M CNY | 407.52M CNY | 468.24M CNY | 481.36M CNY |
| Selling, general, and administrative | 81.65M CNY | 75.11M CNY | 79.34M CNY | 86.94M CNY | 77.55M CNY |
| Operating expenses | 575.99M CNY | 479.26M CNY | 487.09M CNY | 555.18M CNY | 558.91M CNY |
| Interest income | 34.38M CNY | 49.26M CNY | 74.04M CNY | 33.87M CNY | 27.81M CNY |
| Interest expense | 7.26M CNY | 9.92M CNY | 12.18M CNY | 14.21M CNY | 13.18M CNY |
| Depreciation and amortization | 63.01M CNY | 55.78M CNY | 69.12M CNY | 40.54M CNY | 41.1M CNY |
| Operating income | −149.32M CNY | 101.01M CNY | −305.55M CNY | −432.37M CNY | −415.62M CNY |
| Net income | −110.99M CNY | 166.34M CNY | −210.59M CNY | −325.72M CNY | −412.42M CNY |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS6.72M0.00%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Emerging Markets ETFVWO6.36M0.00%162.3B USD0.06%$61.44+0.74%
iShares Core MSCI Emerging Markets ETFIEMG2.9M0.00%161.18B USD0.09%$83.65+1.65%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.94M0.01%13.6B USD0.06%$161.34+0.42%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM328.85K0.00%9.54B USD0.39%$41.00+1.36%
Vanguard Total World Stock ETFVT307.33K0.00%97.9B USD0.06%$161.73-0.02%
iShares MSCI China Small-Cap ETFECNS213.95K0.33%64.72M USD0.59%$29.1927+0.70%
iShares Core MSCI Total International Stock ETFIXUS158.04K0.00%60.45B USD0.07%$98.71+0.57%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE All-World ex-US Small-Cap ETFVSSDimensional - Emerging Markets Core Equity 2 ETFDFEMVanguard Total World Stock ETFVTiShares MSCI China Small-Cap ETFECNSiShares Core MSCI Total International Stock ETFIXUSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
